Please assess the completion status of the following clinical trial:

Trial Title: Simultaneous RZV and aIIV4 Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female age ≥ 65 years~2. Intention of receiving IIV and RZV based on ACIP-CDC guidelines~3. Able to speak English~4. Willing to provide written informed consent~5. Living in the community~6. Intention of being available for entire study period and complete all relevant study procedures, including follow-up phone calls and clinic visits.~7. If HIV positive, HIV should be clinically stable.~Exclusion Criteria:~1. IIV or recombinant influenza vaccine (RIV) receipt during the respective 2021-2022 or 2022-2023 influenza season prior to study enrollment~2. Prior receipt of recombinant zoster vaccine (SHINGRIX®)~3. For non-COVID-19 Vaccines:~   * Receipt of any inactivated vaccine within 2 weeks prior to enrollment in this study~  * Receipt of any live vaccine within 4 weeks prior to enrollment in this study~  * Planning receipt of any non-COVID-19 vaccine during the entire period~4. For COVID-19 Vaccines:~   * Receipt of COVID-19 vaccine within 2 weeks prior to enrollment in this study. For those who have initiated a COVID-19 vaccine series, enrollment is not allowed until 2 weeks after the final dose of a COVID-19 vaccine is completed.~  * Planning receipt of a COVID-19 vaccine within 2 weeks after administration of study influenza and first dose recombinant zoster study vaccines.~5. Have acute illness or exacerbation of chronic illness within 72 hours of study vaccination~6. Hospitalization within the last 30 days for any reason~7. History of febrile illness (\> 100.0°F or 37.8°C) within the past 24 hours prior to IIV administration~8. Has immunosuppression as a result of an underlying illness or treatment, or use of chemotherapy or radiation therapy within the preceding 12 months~9. Has an active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) \*Participants with a history of malignancy may be included if, after previous treatment by surgical excision, chemotherapy or radiation therapy, the participant has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure~10. A history of autoimmune disease, that requires immunosuppressive agents or any other chronic medical condition considered clinically significant by the investigator~11. Use of chronic oral or intravenous administration (≥14 days) of immunosuppressive doses of steroids, i.e., prednisone \>10 mg per day, immunosuppressants or other immune-modifying drugs within 30 days of starting this study. (Use of topical, nasal, or inhaled steroids is permitted)~12. Thrombocytopenia, bleeding disorder, or anticoagulant use contraindicating intramuscular injection (a daily aspirin may be acceptable)~13. Contraindication to IIV receipt including history of severe allergic reaction after a previous dose of any influenza vaccine; or to a vaccine component, including egg protein~14. Contraindication to RZV including history of a severe allergic reaction to any component of the RZV vaccine (including saponin or polysorbate 80) or to dose 2 of RZV~15. History of Guillain-Barré syndrome~16. History of Hepatitis C or active Hepatitis B~17. Receipt of blood or blood-derived products (including immunoglobulin) within 6 months prior to study vaccination~18. Dementia, any cognitive condition, or substance abuse that could interfere with study compliance~19. Anyone who is already enrolled or plans to enroll in another clinical trial with an investigational product within 28 days of vaccine receipt. Co-enrollment in observational or behavioral intervention studies are allowed at any time while enrollment in a clinical trial involving an investigational product (other than vaccine) may occur after 28 days following vaccine receipt~20. Any condition which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives~21. Anyone who is a relative of any research study personnel~22. Anyone who is an employee of any research study personnel

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Influenza Vaccine (FLUAD®) (Type: ACTIVE_COMPARATOR): In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the adjuvanted influenza vaccine (FLUAD® Quadrivalent) simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
- Zoster Vaccine Recombinant (RZV) and High-Dose Quadrivalent Influenza Vaccine (Fluzone®) (Type: ACTIVE_COMPARATOR): In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the (Fluzone® HD Quadrivalent) influenza vaccine simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete